In Prostate Cancer, Focus on AR Signaling Sharpens

Anita T. Shaffer @Shaffer1
Published: Tuesday, Nov 13, 2012
Dr. James L. Mohler

James L. Mohler, MD

The 10th International Congress on Targeted Therapies in Cancer, held August 17-18 in Washington, DC, provided an overview of emerging research into a variety of anticancer targets, including novel hormonal approaches in prostate and breast cancers, and cellsignaling pathways, such as the aurora kinases. Alex A. Adjei, MD, PhD, of Roswell Park Cancer Institute, and John Wright, MD, PhD, of the National Cancer Institute, served as program directors for the meeting, which Physicians’ Education Resource (PER) hosted.

Table. Agents Targeting Androgen Receptor Signaling

Agent Indication

(approved or under study)
Description Sponsors Status
Abiraterone acetate

(Zytiga)
Given in combination with prednisone to patients with mCRPC who have received prior docetaxel Inhibits CYP17 enzyme activity Janssen Biotech (Johnson & Johnson) FDA approved April 2011
Enzalutamide
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
x